Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Amortizatization of Intangibles (2021 - 2025)

Historic Amortizatization of Intangibles for 4D Molecular Therapeutics (FDMT) over the last 5 years, with Q3 2025 value amounting to $1.2 million.

  • 4D Molecular Therapeutics' Amortizatization of Intangibles fell 4848.21% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 532.82%. This contributed to the annual value of $7.2 million for FY2024, which is 36485.44% up from last year.
  • Per 4D Molecular Therapeutics' latest filing, its Amortizatization of Intangibles stood at $1.2 million for Q3 2025, which was down 4848.21% from $1.2 million recorded in Q2 2025.
  • 4D Molecular Therapeutics' 5-year Amortizatization of Intangibles high stood at $2.8 million for Q4 2022, and its period low was -$582000.0 during Q1 2022.
  • Its 5-year average for Amortizatization of Intangibles is $804631.6, with a median of $402000.0 in 2023.
  • The largest annual percentage gain for 4D Molecular Therapeutics' Amortizatization of Intangibles in the last 5 years was 62815.79% (2022), contrasted with its biggest fall of 25945.21% (2022).
  • Quarter analysis of 5 years shows 4D Molecular Therapeutics' Amortizatization of Intangibles stood at $380000.0 in 2021, then skyrocketed by 628.16% to $2.8 million in 2022, then crashed by 85.15% to $411000.0 in 2023, then skyrocketed by 350.12% to $1.8 million in 2024, then crashed by 37.62% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.2 million for Q2 2025, and $1.3 million during Q1 2025.